Cite
Schiff R, Lee AV. Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nat Clin Pract Oncol. 2006;3(3):134-5doi: 10.1038/ncponc0444.
Schiff, R., & Lee, A. V. (2006). Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nature clinical practice. Oncology, 3(3), 134-5. https://doi.org/10.1038/ncponc0444
Schiff, Rachel, and Lee, Adrian V. "Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?." Nature clinical practice. Oncology vol. 3,3 (2006): 134-5. doi: https://doi.org/10.1038/ncponc0444
Schiff R, Lee AV. Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nat Clin Pract Oncol. 2006 Mar;3(3):134-5. doi: 10.1038/ncponc0444. PMID: 16520802.
Copy
Download .nbib
